Sa2006 EUS-GUIDED INJECTION OF INTRATUMORAL SUBMICRON PARTICLE PACLITAXEL (SPP) FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC):PHASE 2 STUDY

Pancreatic cancer is an aggressive malignancy with a 5-year survival rate of 8%. Approximately 30% of all pancreatic tumors present as locally advanced disease (LAPC). Despite recent use of more aggressive chemotherapies and the advances in surgical techniques, the mean survival for most patients with LAPC is approximately 8-13 months. Current chemotherapy agents exhibit systemic toxicities and variable tumor penetrance due to the desmoplastic reaction associated with it. Nanopac is a novel submicron particle paclitaxel (SPP) that can be administered directly into the tumor via EUS.

Source: Gastrointestinal Endoscopy - May 31, 2020 Category: Gastroenterology Authors: Neil R. Sharma, Mohamed O. Othman, Antonio H. Mendoza Ladd, Shelagh Verco, James Verco, Gere diZerega, Simon K. Lo Tags: Poster abstracts Source Type: research